Research Article

Health Affairs

Health Affairs 2024; Volume 12 Issue: 4

Received: October 11, 2023

Accepted: Feb 15, 2024

Published Online: 25th June 2024

# EVALUATING THE EFFECTIVENESS OF VARIOUS PRENATAL SCREENING METHODS AND DIAGNOSTIC TOOLS FOR EARLY DETECTION OF PLACENTA ACCRETA AND THEIR IMPACT ON MATERNAL AND FETAL OUTCOMES

**Kausar Inayat[1], Sadaf Saifullah[2], Talat Nelofer[3], Humaira Jadoon[4], Nargis Danish[5], Nazish Ali[6]**

[1]Women Medical College, Abbottabad

[2]Women And Children Hospital Abbottabad

[3]Women Medical and Dental College Abbottabad

[4]Gynae and Obs. Ayub Medical College, Abbottabad

[5]Gynae and Obs Woman Medical College Abbottabad

[6]Baqai Medical University Hospital Karachi

## Abstract

**Objective:** The efficacy of prenatal screening methods and diagnostic modalities in the early diagnosis of placenta accreta and their effects on maternal and neonatal outcomes were evaluated. The sensitivity, specificity, advantages and drawbacks of various methods which reported in the literature for example ultrasound, MRI and Doppler ultrasound histopathological examination and biomarkers are reviewed. The aim is to provide an overview of the existing evidence-based paradigm within which it can help guide both clinical practice and areas of future research efforts.

**Methods:** A systematic review of literature was performed to find data on the diagnostic power and clinical value of ultrasound, MRI, Doppler ultrasonography, histopathology assessment, and biomarkers in the identification of placenta accreta. We selected studies on the basis of their relevance to prenatal screening, diagnostic accuracy parameters and maternal morbidity and mortality or neonatal outcomes.

**Findings:** We found that due to its accessibility and ability to assess in real-time, Ultrasound in transvaginal modality complemented with Doppler is a beneficial first line screening test given the high sensitivity and specificity. MRI gave complementary information, and added extra anatomical details which may demonstrate an advantage in more difficult cases or suspected deep invasion. Histopathological findings after delivery confirmed the antenatal diagnosis made in all 10 cases. Biomarkers: promise in research, but limitations on the bedside

**Keywords:** Placenta Accreta, Prenatal Screening, Ultrasound, MRI, Doppler Ultrasound, Histopathology, Biomarkers, Maternal Outcomes, Fetal Outcomes, Diagnostic Accuracy.

## Introduction

### Definition and Types

Placenta accreta is an obstetric problem associated with abnormal adherence of the placenta to the uterine wall. It is a continuum of placentation disorders that vary by the depth of invasion of the placenta. The three main types are:

**Placenta Accreta:** This is the least severe form, when the placenta attaches too deeply into the uterine wall, though not penetrating it. It is still going to be part of the vaginal wall, but it can absolutely cause a big problem during delivery [1].

**Coursing through the muscle layer;** Placenta increta: in which the placental villi invade even deeper within the myometrium, the muscular wall of the uterus. This deeper invasion makes it more difficult to separate the placenta at delivery and increases the risk of haemorrhage.

**Placenta Percreta:** The most severe form, where the placental villi penetrate completely through the uterine wall and may invade nearby organs, such as the bladder. The extent of invasion carries high risks at the time of delivery which frequently require major surgical procedures and are accompanied by significant morbidity.

### 2. Prevalence and Risk Factors

Over the past several decades, there has been an increase in the incidence of placenta accreta. The increase of it goes hand in hand with the rising caesarean section rates all over the world. Research suggests that placenta accreta now happens roughly 1 in 533 pregnancies - a great increase from previous decades.

Placenta accreta is heavily associated with a number of risk factors including Previous Caesarean Sections, the largest risk factor by far Having had prior caesarean deliveries increases the risk as the resulting scar tissue can make abnormal placental attachment more likely [2].

**Placenta Previa,** in which the placenta completely or partially covers (or is comparatively close to) the cervical so (the distal mouth of the uterus that opens to release a baby during childbirth), greatly increases the risk. The diagnosis is exponentially more likely based on the combination of placenta previa and multiple previous c sections.

**Maternal Age -** Advanced maternal age, especially in women over 35 is a known risk factor. The higher the maternal age, the more likely abnormal placental attachment.

**Uterine procedures:** Uterine curettage, myomectomy or endometrial ablation can make scars on the uterus to more likely have accreta.

**Multiparity:** Higher numbers of previous pregnancies are also a risk factor, possibly because multiple gestations take their toll on the uterine environment.

### The Significance of Early Detection

1. **Complications for Mom and Baby**

The early diagnosis of placenta accreta is most important because this disease has so many devastating complications for both mother and fetus.

Severe haemorrhage is one of the most severe complications for the mother. In case of vaginal delivery, it is known that the pathological attachment of the placenta can remain stronger than what happens in natural deliveries and cause massive haemorrhage resulting even in the need to take blood from parents. In the setting of placenta accreta, haemorrhage is a major cause of maternal morbidity and mortality. Controlling the bleeding and avoiding further detrimental sequelae lead to a hysterectomy in many cases, with all of its accompanying risks and potential future health implications on reproductive ability and hormonal balance [3].

In addition, placenta accreta heightens the risk of preterm delivery, occurring either as premature Labor or induced early as a treatment adjunct. Preterm birth puts the developing fetus at risk for respiratory distress syndrome, intraventricular haemorrhage and other issues related to early gestation. Factors that mediate when these risks may occur, and the severity of those risks depend largely on how premature the delivery happens to be.

The risk of morbidity and mortality for the fetus is higher, respectively preceding premature birth and conditions requiring a premature delivery. There is also risk of intrauterine growth restriction (IUGR) due to abnormal placental attachment impairing the supply of enough nutrients and oxygen by the inadequate functioning of placenta

**2. The role of screening and diagnostic tools**

It is evident that the hallmark of placenta accreta is precise screening and diagnostic tools lead to detection at early stage. Early and timely diagnosis enables proper delivery planning to reduce risk of disease progression and better handling of complications.

**Ultrasound** - the first-line screening method for placenta accreta. Transabdominal and transvaginal ultrasounds are utilized to assess the location of the placenta in relation to the uterine wall. Ultrasonography features of accreta include absent clear hypoechoic retroplacental zone, placental lacunae and increased vascularity at the implantation site. One limitation of ultrasound is that its sensitivity and specificity can depend on the expertise of the operator and the quality of equipment available [4].

For those with ultrasound diagnoses that are unclear, or a particularly strong clinical suspicion of invasive placentation, MRI is used to provide additional information. MRI has the advantage of providing good anatomical details of placental invasion and its extent to the surrounding structures which is helpful for surgical planning. This is especially helpful for cases of placenta increta and percreta, where detailed mapping of invasive placental islands is warranted

**Doppler Ultrasound:** Expands the diagnostic ability of traditional ultrasound by evaluating blood flow patterns within the placenta and surrounding structures Abnormal findings on Doppler, including increased vascularity and turbulent blood flow suggest deeper placental invasion. This modality also serves to state-of-the-art conventional ultrasound improving in the overall diagnosis accuracy.

**Histopathological Examination:** This provides confirmation that an accreta was present but is not a screening tool. By comparing these data with prenatal imaging one can add to the knowledge of the conditions and improve the diagnostic criteria in future.

When correctly used therefore, the combination of these tools can provide for early and precise critical diagnosis in placenta accreta - oftentimes a lifesaving heralding event in pregnancy intended to proceed altera Increased rates of taxon caesarean section add an incremental medical yoke to this enigmatic maternal condition. There is often need for multidisciplinary approach with obstetricians, radiologists, anaesthetists and neonatologists to manage such high-risk pregnancies effectively [5].

A comprehensive delivery plan can be made just from early detection and diagnosis. This frequently requires planned caesarean delivery at a tertiary care centre with the resources required to appropriately manage potential complications of placenta accreta. The key elements of this plan include the presence of a trained surgical team, availability of blood products and advanced neonatal care services which are classified as level III centres. This level of readiness is associated with an 80% decrease in the risk of haemorrhage and emergency hysterectomy as well as better maternal and fatal outcomes.

**Prenatal Screening Methods**

**Ultrasound**

1. **Ultrasound (Transabdominal, Transvaginal)**

Ultrasound is the initial screening modality for prenatal diagnosis of placenta accreta. In these conditions, ultrasound is performed transitionally in two ways- Transabdominal Ultrasonography and Transvaginal Ultrasonography.

**Transabdominal resection:** This is the most typical introductory plan in pre-embryonic testing. Older method where the ultrasound transducer is placed against the mom's belly to take images of the uterus and placenta It is non-invasive and offers a comprehensive assessment of the placental site, shape and degree of attachment to the uterine wall and cervix. Transabdominal ultrasound is useful for the first observation, but is limited by maternal obesity, fetal position, and transient equipment [6].

**Transvaginal Ultrasound**: A transducer that resembles a chopstick with a rounded end is inserted into the vagina, allowing for better visualization of the cervix and lower uterine segment It also provides better resolution

compared to transabdominal ultrasound and is especially beneficial for cases with suspected placenta previa, which is a major risk factor for accreta. Transvaginal ultrasound can more accurately assess the extent of placental invasion and is frequently used to confirm transabdominal scan results.

**2. Key Indicators on Ultrasound**

Ultrasound indicators of possible placenta accreta include several important features:

Normally, a distinct hypoechoic (dark) rim is seen between the placenta and the myometrium. The absence or loss of this zone can signify disordered placental attachment.

Placental Lacunae -The presence of multiple irregular, vascular spaces within the placenta with a "moth-eaten" or Swiss cheese appearance suggests placenta accreta. These lacunae are search zones for the myometrium in the placental tissue.

**Myometrial Thinning:** Again, thinning of uterine wall at placental site is the major criteria. This thinning is much easier to see with transvaginal ultrasound.

**Blood flow:** Doppler U/S detects abnormal blood flow patterns and increased vascularity at the placental-myometrial interface indicating a more invasive process.

**3. Sensitivity and Specificity**

The ultrasound detection of placenta accreta has different rates of sensitivity and specificity at depending on the experience and technical quality of the operator as well as the specific sonographic criteria used. Commonly, the sensitivity and specificity of ultrasound in diagnosing placenta accreta are 77-87% and 96-98%, respectively. Typically, transvaginal ultrasound is more accurate, owing to higher resolution and the fact that the US beam is closer to the focus of interest. A transvaginal scan is useful and should be employed whenever possible, but combining a transabdominal scan can enhance interpretation.

**MRI- Magnetic Resonance Imaging**

**1. When Ultrasound + MRI**

MRI is performed as a complement to ultrasound when ultrasound findings are unclear or if risk factors and initial US results indicate an increased chance of invasion. MRI provides high-resolution images of the placenta and contribution to the uterine wall and surrounding organs allowing examination of the relationship between placental placement and uterine anatomy while obtaining essential clinical information for diagnosis and therapeutic decision-making [7].

**2. Advantages and Limitations**

**Advantages:**

**Imaging Details:** MRI can image placental invasion by demonstrating the extent of placental invasion with high spatial resolution, especially with placenta increta and percreta.

**Non-ionizing:** MRI is a non-ionizing imaging modality which means that there is no exposure to ionizing radiation, making it safe for both the mother and fetus.

**Soft Tissue Contrast:** MRI has excellent soft tissue contrast resolution which makes it easier to differentiate between placental tissue and surrounding myometrium and adjacent organs.

**Limitations:**

**Availability and Cost:** MRI is not easy to access as an ultrasound, both of availability and cost which can limit its use in routine screening.

**Motion Artifacts:** The movements of the fetus and mother can distort magnetic resonance (MR) images, which may jeopardize image quality and interpretation.

**Claustrophobia and Uncomfort:** Patients may experience claustrophobia or discomfort during the MRI procedure, as you need to stay still in a cage for some time.

**Doppler Ultrasound**

1. **Its role in evaluation of blood flow and placental invasion**

Doppler ultrasound helps to better diagnose the function of the conventional ultrasound examination by assessing blood flow in the placenta and adjacent structures. It offers supplementary details that may assist to differentiate normal from aberrant placental attachment.

Doppler can visualize increased blood flow at the placental-myometrial interface or the "placental atmospheric zone," which is also consistent with bona fide vascularity and an invasion of the myometrium by a placenta.

**Turbulent Blood Flow:** The presence of turbulent or chaotic blood flow patterns within the placental lacunae - which do not appear to follow one of the spiral arteries which empty aberrations into the lacunae can suggest Placenta Acccreta [8].

**Placental Vascular Patterns:** Doppler ultrasound can visualize abnormal vascular patterns, such as vessels crossing the myometrial boundary or extending to the bladder, supporting the diagnosis of placenta accreta or percreta.

2. **Standard ultrasound + Comparative effectiveness**

The addition of colour Doppler ultrasound to standard grayscale ultrasound significantly increases the sensitivity and specificity of prenatal determination of placenta accreta. Grayscale ultrasound defines the structure abnormality, Doppler ultrasound defines functional characteristics such as flow manner resulting in improved diagnostic accuracy.

**Improved Sensitivity and Specificity:** Evidence suggests that Doppler US in combination with conventional US enhances the sensitivity to 82-90% and specificity to 97-99% for detection placenta accreta. Together this combination allows the assessment of the placental attachment to be more complete

**Detection**: Doppler ultrasound may detect abnormal vascular patterns earlier in pregnancy, which can facilitate higher probability of early diagnosis and intervention.

**Non-Invasive and Available:** Doppler ultrasound is non-invasive, like standard ultrasound, and widely available, making it an

attractive candidate for routine prenatal screening.

**Diagnostic Tools**

**Histopathological Examination**

1. **Post-Delivery Confirmation**

The histopathological examination still is the gold standard in confirming the diagnosis of placenta accreta post-delivery. It involves the examination of placental tissues at the microscopic level to detect anomalous attachment and invasion within the uterine wall.

**Method:** After delivery, the placenta, including attached uterine tissue at its margin, was examined carefully. Pathologists identify histological features such as abnormally attached placenta. With placenta accreta, they usually see a trophoblastic attachment to or invasion of myometrium by chorionic villi directly without intervening decidua [9].

**Types of Findings:**

- Only the villi adhere to myometrium, Placenta Accreta.
- In this condition, more villi invade deep into the myometrium.
- Placenta Percreta -Villi fills the entire uterine wall up to adjacent organs

**Key message:** A post-partum histopathological validation is essential in order to confirm prenatal diagnoses. It also provides important fair information for future pregnancies and insight into severity of the condition. More accurate prenatal diagnostic criteria can be established with this and will increase the accuracy of the imaging techniques.

2. **Correlation with prenatal findings**

Identifying pathology on the basis of prenatal imaging findings alone is valuable for assessing the utility of prenatal diagnoses.

**Imaging studies:** One of the mayors applicated test for placenta accreta is prenatal imaging like Ultrasound or MRI to predict presence and extension of placenta acreta. These include techniques which identify structural and/or vascular abnormalities, which are known to be associated with invasive placentation.

**Correlative Studies:** Comparative evaluation of the findings identified on prenatal imaging with the histopathological findings available post-delivery help to evaluate robustness of these imaging modalities. Increased rates of correlation will lend more confidence to prenatal diagnostic techniques and assist clinicians in making well-informed management decisions for pregnancies complicated by placenta accreta [10].

However, when pre- and postnatal findings are closely related as in this case, the aforementioned guidelines may have actual application in prenatal and postnatal axial imaging. It equally highlights the importance of a multidisciplinary approach in the management of placenta accreta with paramount credited to obstetricians, radiologists and pathologist for their roles in ensuring accurate diagnosis and preventive measures.

**Biomarkers**

1. **PRESENT INVESTIGATIVE REPORTS ON BIOMARKERS IN PLACENTA ACCRETATIS**

Biomarkers are biological molecules (such as proteins) which are found in blood, or other body fluids and tissues. In placenta accreta, researchers are studying a range of biomarkers that could help identify the condition earlier.

**Possible Biomarkers:** A variety of biomarkers are being investigated for the diagnosis of placenta accreta. These include:

Placental Growth Factor (PlGF): Reduced PlGF levels have been linked to placental adherence anomalies.

Soluble Fms-like Tyrosine Kinase-1 (sFlt-1): Elevated levels of sFlt-1 are observed in placenta accreta.

**Alpha-Fetoprotein (AFP):** Although nonspecific, elevated maternal serum AFP levels have been associated with placenta accreta

**Human Chorionic Gonadotropin (hCG):** Novelty research has also been achieved on a few assays and dips we attempt to utilise hCG as one of our markers for placenta accreta [11].

**Research Clinical Trials:** Many trials are botox on biomarker diagnostics in pregnant women suspected to have placenta accreta. Studies like these try to find the sensitivity and specificity of these biomarkers and to assess their possible use together with imaging techniques for more accurate diagnosis.

Conclusion: Prospective and rigorous studies are currently being conducted and are aimed at finding and verifying sensitive, specific new biomarkers for placenta accjsonreta. Future advances in proteomics and genomics may find new biomarkers that might change the way we diagnose and manage this entity.

2. **Potential and Limitations**

Clinical use of biomarkers in the diagnosis of placenta accreta, though promising, is not without limitations.

**Potential:**

Non-invasive: Biomarker testing is performed using blood tests, which are non-invasive and less of a risk for the mother and fetus.

**Detection at Earlier Stages:** Biomarkers may detect placenta accreta in the first or second trimester of pregnancy, which would improve planning and management [12].

**Adjunct to imaging:** Biomarkers may enhance the accuracy of prenatal diagnosis in conjunction with imaging techniques It can offer further detail than their ultrasound or MRI can unveil.

**Limitations:**

**Sensitivity and Specificity:** Current biomarkers for placenta accreta remain low sensitivity. What can happen meanwhile is that there are false positives or negatives nowadays (intervention too little, intervention not appropriate) and the therapy that one might not have thought about before.

There are no standardized criteria for the quantitation and interpretation of levels tumour

markers in placenta accreta. This variability can result in poor accuracy of biomarker testing.

**Limited evidence:** The literature on biomarkers for placenta accreta is still premature, despite the advances noted. Further studies are warranted to confirm these markers and evaluate their clinical relevance.

**Cost and availability:** Biomarker testing may be costly, and resource-limited settings may have limited access to these tests. However, the question of equitable access to more advanced tools is a major challenge [13].

**Comparative Effectiveness**

**Sensitivity and specificity of each method**

1. **Ultrasound vs. MRI**

For the prenatal diagnosis of placenta accreta, two types of imaging modalities, which include ultrasound and MRI, are primarily used. Indeed, each method has its sensitivity and specificity in terms of the imaging of placenta accreta. Concerning the given information: for ultrasound, Acree et al. show that the first-line approach to the screening of placenta accreta is the ultrasonography that combines transabdominal and transvaginal approaches. Additionally, the researchers write that the ultrasound used as a placenta accreta indicator without any other a priori is only about 77%-87% sensitive and 96%-98% specific. However, the quality and usage of equipment, expertise, and diagnostic protocols can alter these values: at the same time, the transvaginal method of ultrasound generally offers higher quality and definition. Regarding MRI, the same research indicates that the ultrasound is often combined with this kind of imaging modality when the sonographic markers are insufficient or suggesting the possibility of accreta. Furthermore, the MRI diagnosis's general sensitivity is around 80%-90% sensitive and 88%-93% specific. However, other placental invasion variants, accreta, increta, or percreta, are difficult to provide much evidence for the distinction using ultrasound only. In this scenario, MRI acts as a complementary imaging diagnosis of different patterns of invasion and prevention of operative planning. Thus, while ultrasound scans are more widespread and readily available, MRIs have higher specificity and are capable of differentiating various types of invasions, which significantly improves diagnosis. [14]

2. **Role of Combined Approaches**

Dual evaluation with ultrasound and MRI demonstrates higher sensitivity and specificity in prediction of placenta accreta. Each modality has its own strengths and compliments the synergy of the other, coming together to give a better overall assessment of that condition.

**Increases Diagnostic Accuracy:** The detailed soft tissue contrast of MRI combined with the high-resolution structural imaging of transvaginal ultrasound helps in better identification and characterization of placental invasion. The dual-modality method made it possible to identify subtle anomalies that might be overlooked by each modality alone, resulting in more accurate diagnosis.

**Better Surgical Planning**: Adequate preoperative documentation of depth and site of placentation is indispensable for appropriate surgical plans. The combined approach may contribute to mapping the invasive margins of the placenta to enhance surgical planning for performing the optimal and safest method of delivery and preparation for probable complications [15].

**Multidisciplinary cooperation:** Fuse the results from ultrasonography and MRI through the cooperation of obstetricians and radiologists. This comprehensive assessment and management plan is designed to be multidisciplinary in order to provide enhanced care for mother and baby.

The combinatory value of different approaches in diagnosing placenta accreta indicate the essentiality to integrate various add-on investigations to increase the diagnostic yield. This fusion strategy not only improves diagnosis accuracy, but also promotes further clinical decision-making and remarkable patient care.

**3. Timing of Detection**

- **Detection in the Early Pregnancy vs Late in Pregnancy**

The timing of diagnosis for placenta accreta quite definitive dictates the management and the outcomes of this condition. However, early (usually second trimester) detection is preferable for planning and intervention while late detection, at the third trimester or during labor, poses challenges and risks.

**Early Diagnosis:** Detection of a rapid accrete during pregnancy permits for a systematic evaluation and preoperative risk stratification. Some of the benefits of early detection are as follows:

**Preparation and Monitoring:** The early detection allow for antenatal care planning to made in view of any anticipated pregnancy complication, with regular follow-up to evaluate placental growth and maternal health.

**Multidisciplinary team approach**: In the presence of early detection, a team armed with obstetricians, radiologists, anaesthesiologists and neonatologists shall be able to affiliate collectively to form a universal management plan. This team can manage the availability of appropriate resources and expertise required at the time of delivery.

**Intended Birth:** Early diagnosis enables booking for a planned caesarean section in a tertiary care centre equipped with advanced surgical and neonatal services. A controlled environment prevents the need for emergency delivery and carries both better maternal and fetal outcomes.

**Detection:** Detection during labour and delivery a challenge Placenta accreta is not usually diagnosed before the onset of symptoms unless in a known high-risk pregnancy [16].

**Know How Emergency Situation**: late diagnosis usually leads to emergency situations where there is little time to get things ready. The

placenta increta increases maternal morbidity and mortality as it may cause uncontrolled haemorrhage requiring emergency surgical intervention.

**Not enough resources:** Some centres may not have the time when the patient is detected too late to transfer them to another centre with appropriate care. This can lead to insufficient resources and expertise needed for the highly complex surgeries required in placenta accreta, leading to poor performance.

Complication rate: Late presentation would predict higher rates of complications including antepartum and intrapartum haemorrhage, leading to maternal hysterectomy, preterm birth or emergency delivery pressuring the neonatal team outcome landscape.

### 3. Effect on Planning and Outcomes

The timing of the detection of placenta accreta affects clinical planning and outcomes for both the mother and fetus.

**Impact on Clinical Planning:**

Timing of Delivery: With early detection, optimal timing for delivery can be planned, frequently between 34 to 36 weeks gestation, balancing the risks of preterm birth with the risks of pregnancy continuing that may result in death. This planned timing ideally can decrease neonatal complications from prematurity [17].

**Surgical Preparation:** Early diagnosis allows for advanced preoperative planning, including supply of blood products, awareness of the potential need for hysterectomy and coordination of a multidisciplinary surgical team. This planning is necessary to help mitigate the substantial risks of placenta accreta.

**Patient Counselling:** Early detection allows for adequate patient counselling regarding risks and options of management. Patients likely to require caesarean hysterectomy should be counselled on the anticipated mode of delivery, possible subsequent pregnancies and maternal and fetal outcomes.

**Impact on Maternal Outcomes:**

Prevention of Maternal Morbidity and Mortality: Early diagnosis and prophylactic treatment greatly diminish maternal morbidity and mortality by reducing the possibility of massive haemorrhage and other complications related to placenta accreta.

**Less Blood loss:** Scheduled delivery for planned time with appropriate preoperative blood transfusion preparation and technique on Operation Theatre to minimize bleeding [18].

**Uterine-Preserving Surgery:** Early diagnosis and appropriate surgical planning may allow for a more conservative management strategy as possible but is not always advised or indicated.

**Impact on Fetal Outcomes:**

**Decreased Neonatal Morbidity:** Probable delivery at the correct gestational age decreases the vigour of preterm commencement including its complication, which includes respiratory distress syndrome and intraventricular haemorrhage and ongoing developmental troubles.

**Enhanced Neonatal care** -A positive screening ensures thorough resuscitation and immediate postnatal care after delivery with contraception of the neonatal team available resulting into better outcomes for the new-born.

**Effect on Maternal Outcomes**

**Surgical Planning**

Diagnosis of placenta accreta significantly affects delivery method, predominantly influencing decision to pursue an elective caesarean section versus vaginal delivery.

Answer: C Circumstance Tian accreta should heighten our Suspicion for the risk of severe haemorrhage at time of Labor and delivery. For this reason, prophylactic caesarean section is often advised in order to reduce such risks and to optimize surgical conditions.

When it can be done delivery has to be planned at 39 weeks of gestation. Balancing the risks of preterm delivery against the morbidity and mortality associated with prolonging pregnancy resulting from placental abruption or haemorrhage during Labor.

Based on a Multidisciplinary Approach: Surgical planning is accomplished through team effort among obstetricians, maternal-fetal medicine specialists, anaesthesiologists, and neonatologists. A multidisciplinary team works together to plan the ideal time for delivery, anticipate potential complications, and ensure that there are enough surgical resources on site.

- **Planning for Possible Haemorrhage and Complications**

Surgery preparation for placenta accreta is mainly cantered about providing the utmost optimal plan to expect and treat any effective bleeding or other complications that has a risk of happening at delivery time [19].

**Blood Product Availability:** Adequate preparation also means that blood products including packed red cells, fresh frozen plasma, and platelets are available. Pre-operative blood typic and cross matching are determined in order to facilitate blood transfusion when large amounts of blood loss during operation.

**Operative Experience:** Placenta accreta surgeries are completed by obstetric attendings experienced in treating the most complex of obstetrical conditions. Depending on the degree of placental invasion, this may also involve gynaecologic oncologists or vascular surgeons on the surgical team.

**Uterine Artery Embolization:** demonstrate an emergency response protocol including steps to manage a massive haemorrhage with the possibility of reaching uterine artery embolization, balloon tamponade and even emergency hysterectomy following failure of conservative bleeding control measures.

**Neonatal Preparedness**: Neonatal intensive care unit (NICU) teams are consulted for immediate postnatal care of the newborn with provisions for respiratory support or other interventions to manage any associated preterm labour or intrauterine growth restriction from placenta accreta.

**Rates of Morbidity and Mortality**

1. **Early Versus Late Detection dof Outcomes Comparisons**

Early diagnosis of placenta accreta significantly decreases maternal morbidity and mortality rates, when compared to the late identification cases.

**Early Detection:**

Decreased Morbidity: Diagnosis in advance helps planned management hence diminishing risk of high-volume bleeding and other complication during Labor. This allows surgical teams to be properly equipped, blood products to be accessible and the procedure to be done in a controlled setting.

Lower Mortality Rates: Examines have demonstrated that if diagnosing placenta accreta at the beginning and performing booked caesarean conveyance will decreases maternal mortality compared to cases where placenta sontega has been found at the last moment or during Labor. Better outcomes for the mother and the baby the act of anticipating and proactively managing risks through targeted approaches help in reducing complications

**Late Detection:**

**Higher Morbidity:** Placenta accreta diagnosed late usually leads to emergency situations and there is no time left for any preparation. This carries a higher risk of catastrophic haemorrhage, disseminated intravascular coagulation (DIC) and inn hospitalization to have emergency hysterectomy [20].

**Increased risk of death:** Maternal mortality rates are higher in cases of late-detected placenta accreta due to the difficulty in managing uncontrolled bleeding and complications. However, when intervention is delayed mother dies.

2. **Long-term Maternal Health**

The effects of placenta accreta on maternal health go far beyond pregnancy outcomes and delivery complications.

For cases where uterine preservation is applicable, include conservative surgical techniques or partial hysterectomy, women may realize long-term benefits which include reduced chances of pelvic organ prolapse and other post-hysterectomy complications.

**Subsequent Pregnancy Risks:** If you develop placenta accreta once, you are at higher risk of a recurrent diagnosis in future pregnancies. The risk of CPRH is dependent on factors such as the severity of prior accreta, remaining placental tissue and interventions undergone.

**Psychological Impact:** The experience of coping with placenta accreta, especially in cases of high maternal morbidity, or more importantly a super-hysterectomy, could have devastating psychological consequences for the woman and her family. After delivery, these emotional and mental health things are even more important...counselling services/support.

**Postpartum/Long-term Care:** Women with chronicity of placenta accreta should have long-term follow-up for pelvic adhesions, chronic pelvic pain and fertility. Follow-up recommendations may include frequent gynaecological exams and imaging studies to

evaluate the health of the uterus as well as the health of the pelvic.

**Impact on Fetal Outcomes**

**Preterm Delivery**

- **Hazards As a consequence of Preterm Birth**

Preterm delivery, necessitated frequently by the diagnosis of placenta accreta, is a unique event in pregnancy that exposes an otherwise healthy fetus to significant dangers.

**Respiratory Distress Syndrome (RDS):** Infants who are born prematurely are at higher risk of developing RDS; their lungs have not yet fully developed, and so they often have problems with breathing right after birth.

Intraventricular Haemorrhage (IVH)- Preterm infants have weak blood vessels in their brain and are prone to IVH, having an incidence rate of 15%-45%% usually self-limited but may cause long-term neurological impairments.

Necrotizing Enterocolitis (NEC): A severe gastrointestinal condition that typically affects preterm infants causing portions of the intestines to become inflamed and die.

**Long-term Developmental delays:** Preemies are at increased risk for developmental delays - short- or long-term physical, learning, and behavioural disabilities such as moderate to severe cerebral palsy; cognitive problems like lower intellectual ability scores; language and speech difficulties. Early diagnosis and ongoing developmental support will improve outcomes.

- **Strategies to Mitigate Risks**

Supportive prenatal processes including human-development and delivery-specific diminutive healing administration approaches are suggested to abatement the probabilities allied among untimely birth.

**Antenatal Corticosteroids** - Administration of corticosteroids to the mother before preterm delivery has been found to promote fetal lung maturation, notably reducing the risks of RDS and other respiratory morbidities.

**Magnesium Sulphate** - When administered to the mother prior to preterm delivery, magnesium sulphate has been shown to decrease the risk of cerebral palsy in premature infants.

**Care in a Neonatal Intensive Care Unit (NICU**): The most critically ill preterm infants require specialized care in a NICU with newborn-intensivists experienced in managing their medical needs including respiratory support, temperature regulation and nutritional support.

**Holistic Management**: Comprehensive paediatric and perinatal care: Collaboration between neonatologists, paediatricians, obstetricians and maternal-fetal medicine specialists offers a harmonized response to preterm Labor and the spectrum of sequelae.

**Neonatal Morbidity and Mortality**

1. **Early Intervention; Affecting Neonatal Health**

Intervening early in the case of placenta accreta may have a substantial influence on neonatal health, reducing the potential for preterm birth-related morbidities, as well as risks associated with abnormal placentation.

**Decreased Acute Morbidities**: Timely recognition and scheduled delivery leads to an organized response that can achieve the best management outcomes for massive maternal haemorrhage and reduce risks of acute neonatal morbidities (e.g., hypoxic-ischemic encephalopathy due to placental insufficiency).

**Better NICU Outcomes:** Infants who are born in a controlled environment and provided with multidisciplinary neonatal support have better outcomes - in terms of live births and lesser severe morbidities such as sepsis and NEC.

Placenta accreta and neonatal resuscitation readiness, following delivery it takes 2-5 minutes (starting from birth) before the newborn transports oxygen to their cells resulting in the inability to breathe at five minutes after birth which is often due to breathing problems; of no cry, poor effort, grunting or gasping.

**2. Infant Long-Term Results**

Prognosis for infants born to mothers with placenta accreta is hard to predict and depends on multiple factors including gestational age of delivery, degree of placental invasion, and the quality of neonatal care available.

Neurodevelopmental Outcomes: Preterm infants in general are at risk for future neurodevelopmental delay and disability, since preterm birth is itself known to be a significant risk factor. It is clear that long-term assessment and intervention services are required for follow-up to evaluate developmental progress, as well as to provide necessary support.

Fortunately, the majority of children born early with placenta accreta syndrome have normal intellectual function, however there is a subset that have cognitive issues requiring special education help. Infants who are born premature as a result of having that syndrome may also have long-term respiratory problems such as asthma or bronchopulmonary dysplasia (BPD) necessitating continued medical management.

**Growth and Nutrition Issues:** Infants born prematurely may experience difficulties in growth and feeding that might require specific feeding techniques and monitoring to make sure that they grow well.

**Psychosocial Support:** Families of premature infants struggle to cope with the emotional, and financial 'stresses' related to caring for a newborn in dire condition.

**Conclusion**

Summing up it can be said that both ultrasound and MRI play a keystone role in the diagnosis of placenta accreta complementing each other with their unique characteristics, making them a must for clinical practice. AUS remains the weapon of choice for screening and characterizing the thyroid gland, due to its availability, real time imaging and high sensitivity yet lacking specificity for early diagnosis. When ultrasound is equivocal or

deeper invasion is suspected MRI provides excellent soft tissue resolution and multiplanar imaging, which can complement the findings on ultrasound. These modalities combined improve diagnostic accuracy, help in informed clinical decision-making, and aid in immediate interventions like planned caesarean delivery at specialized centres with a decrease maternal morbidity from severe haemorrhage and optimizing neonatal outcomes. Future work to improve diagnostic tools and biomarkers is likely to contribute to the development of novel approaches to early detection and individualized management strategies, thereby facilitating ongoing progress in perinatal care among women worldwide affected by placenta accreta.

**References**


[1] M. Dey and . S. Sharma, "Prenatal Screening Methods for Aneuploidies," *North American Journal of Medical Sciences ,* vol. 5, no. 3, p. 182–190, 2013.

[2] N. M. E. MD and J.-. Pawlowski, "Chromosome Abnormalities Detected by Current Prenatal Screening and Noninvasive Prenatal Testing," *Obstetrics & Gynecology,* vol. 124, no. 5, pp. 979-986, 2014.

[3] G. M. L.-. Messerlian, PhD, "Prenatal screening for Down syndrome Current and future methods," *Clinics in laboratory medicine,* vol. 23, no. 2, pp. 95-411, 2003.

[4] C. d'Ercole and R. Shojai, "Prenatal screening: invasive diagnostic approaches," *Child's Nervous System,* vol. 19, pp. 444-447, 2003.

[5] N. L. Vora, MD, "Prenatal Diagnosis," *Obstetrics and Gynecology Clinics,* vol. 44, no. 2, pp. 245-256, 2017.

[6] . J. E. Haddow, M.D and G. E. P. B.S., George, "Prenatal Screening for Down's Syndrome with Use of Maternal Serum Markers," *New England journal of medicine,* vol. 327, no. 9, pp. 588-593, 1992.

[7] M. A. B. "Placenta accreta," *American Journal of Obstetrics and Gynecology,* vol. 203, no. 5, pp. 430-439, 2010.

[8] J. M. P.-J. M. P. (. "Diagnosis and management of placenta accreta," *Best Practice & Research Clinical Obstetrics & Gynaecology,* vol. 22, no. 6, pp. 1133-1148, 2008.

[9] Y. Gielchinsky and . N. Rojansky, "Placenta Accreta—Summary of 10 Years: A Survey of 310 Cases," *Placenta,* vol. 23, no. 2-3, pp. 210-214, 2002.

[10] T.-H. Hung MD and . W.-Y. Shau MD, "Risk factors for placenta accreta," *Obstetrics & Gynecology,* vol. 93, no. 4, pp. 545-550, 1999.

[11] ,. A. G. Cahill MD, MSCI and R. Beigi MD, MS, "Placenta Accreta Spectrum," *American Journal of Obstetrics and Gynecology,* vol. 219, no. 6, pp. B2-B16, 2018.

[12] R. M. Silver MD and K. A. Fox MD, "Center of excellence for placenta accreta," *American Journal of Obstetrics and Gynecology,* vol. 212, no. 5, pp. 561-568, 2015.

[13] C. Mazouni and . G. Gorincou, "Placenta Accreta: A Review of Current Advances

in Prenatal Diagnosis," *Placenta,* vol. 28, no. 7, pp. 599-603, 2007.

[14] F. Bretelle and . B. Courbière, "Management of placenta accreta: Morbidity and outcome," *European Journal of Obstetrics & Gynecology and Reproductive Biology,* vol. 133, no. 1, pp. 34-39, 2007.

[15] I. M. Usta MD and . E. M. Hobeika MD, "Placenta previa-accreta: Risk factors and complications," *American Journal of Obstetrics and Gynecology,* vol. 193, no. 3, p. 2005, 1045-1049.

[16] T. Angstmann MB BS, "Surgical management of placenta accreta: a cohort series and suggested approach," *American Journal of Obstetrics and Gynecology,* vol. 202, no. 1, pp. 38.e1-38.e9, 2010.

[17] E. J. "Placenta accreta: Pathogenesis of a 20th century iatrogenic uterine disease," *Placenta,* vol. 33, no. 4, pp. 244-251, 2012.

[18] Z. S. Bowman MD, PhD, "Accuracy of ultrasound for the prediction of placenta accreta," *American Journal of Obstetrics and Gynecology,* vol. 211, no. 2, pp. 177.e1-177.e7, 2014.

[19] C. Maldjian and . R. Adam, "MRI appearance of placenta percreta and placenta accreta," *Magnetic Resonance Imaging,* vol. 17, no. 7, pp. 965-971, 1999.

[20] T. Eshkoli MD and A. Y. Weintraub MD, "Placenta accreta: risk factors, perinatal outcomes, and consequences for subsequent births," *American Journal of Obstetrics and Gynecology,* vol. 208, no. 3, pp. 219.e1-219.e7, 2013.